Enliven Therapeutics (NASDAQ:ELVN) Price Target Raised to $73.00

Enliven Therapeutics (NASDAQ:ELVN) had its target price upped by Mizuho from $62.00 to $73.00 in a research report report published on Tuesday,Benzinga reports. They currently have an outperform rating on the stock.

A number of other brokerages have also issued reports on ELVN. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Friday, July 17th. Wall Street Zen lowered Enliven Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Stifel Nicolaus lifted their price objective on shares of Enliven Therapeutics from $80.00 to $82.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Guggenheim reduced their price objective on shares of Enliven Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Finally, The Goldman Sachs Group increased their target price on shares of Enliven Therapeutics from $67.00 to $80.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Eight research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $75.00.

Enliven Therapeutics Trading Down 0.8%

ELVN opened at $58.92 on Tuesday. The business’s 50 day moving average is $52.72 and its 200-day moving average is $41.84. The stock has a market cap of $4.32 billion, a PE ratio of -35.28 and a beta of 0.27. Enliven Therapeutics has a twelve month low of $14.78 and a twelve month high of $62.32.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.10). As a group, analysts forecast that Enliven Therapeutics will post -1.69 EPS for the current year.

Insiders Place Their Bets

In other Enliven Therapeutics news, Director Mika K. Derynck sold 158,795 shares of the stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $60.21, for a total transaction of $9,561,046.95. Following the completion of the transaction, the director directly owned 87,373 shares of the company’s stock, valued at approximately $5,260,728.33. This trade represents a 64.51% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock in a transaction on Monday, August 17th. The shares were sold at an average price of $58.58, for a total value of $352,534.44. Following the transaction, the chief financial officer owned 40,036 shares in the company, valued at approximately $2,345,308.88. This trade represents a 13.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 196,849 shares of company stock worth $11,344,257 over the last ninety days. Company insiders own 3.00% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. BlackRock Inc. acquired a new position in shares of Enliven Therapeutics in the 2nd quarter worth approximately $221,255,000. Vestal Point Capital LP lifted its stake in Enliven Therapeutics by 230.2% during the fourth quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company’s stock valued at $58,982,000 after purchasing an additional 2,670,000 shares during the last quarter. Siren L.L.C. acquired a new stake in Enliven Therapeutics during the first quarter valued at approximately $29,252,000. Jupiter Topco LLC bought a new stake in Enliven Therapeutics during the second quarter worth approximately $30,617,000. Finally, Affinity Asset Advisors LLC acquired a new position in Enliven Therapeutics in the first quarter worth approximately $23,007,000. 95.08% of the stock is owned by institutional investors and hedge funds.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.